Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Tunlametinib + PD-1 Antibody in Advanced Gastric Cancer
NCT07507526Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin, tunlametinib and tislelizumab in gastric adenocarcinoma, sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate up to 24 months. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
disitamab vedotintunlametinibtislelizumab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT07507526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07507526.